Nubeqa strength boosts Orion shares

Orion Oyj

25/02/2025 11:38

** Shares in Orion  ORNBV.HE  rise as much as 6% after the
Finnish drugmaker published its full quarterly report with
upbeat Nubeqa comments
    ** Q4 revenue and EBIT were in line with pre-announcement
but Jefferies highlights that sales of Nubeqa, Orion's prostate
cancer treatment, were up 60% quarter-on-quarter
        ** The broker also said that although Orion's 2025
outlook at midpoint is broadly in-line with consensus on sales
and 6% below on EBIT, in its view it reflects a typical
start-year conservatism
    ** "We continue to remain optimistic on Nubeqa's ability to
outperform and set into motion a series of outlook upgrades over
the quarters," Jefferies says
    ** Orion expects net sales of EUR 1.55-1.65 billion,
operating profit of EUR 350-450 million in 2025 
        ** Nubeqa royalties and product sales are expected to
clearly increase in 2025, the group added    
  
    ** Orion share is among top movers of the pan-European STOXX
 .STOXX  index

 (Reporting by Elviira Luoma)
 ((Elviira.luoma@thomsonreuters.com))